Loading..

Rigel Pharmaceuticals, Inc. (RIGL) Report Analysis

Corporate Events

Positive

Rigel Pharmaceuticals, Inc. Announces Top-Line ...

2022-06-08 11:00:00

Rigel Pharmaceuticals, Inc. announced top-line efficacy and safety data from the FORWARD Phase 3 clinical trial, a global, multi-center, rando...

Neutral

Rigel Pharmaceuticals, Inc. - Special Call

2022-06-08 11:00:00

Rigel Pharmaceuticals, Inc. - Special Call

Neutral

Knight Therapeutics Inc. Enters into Exclusive ...

2022-05-24 11:30:00

Knight Therapeutics Inc. announced that it has entered into exclusive license and supply agreements with Rigel Pharmaceuticals granting Knight...

Neutral

Rigel Pharmaceuticals, Inc. to Report Q1, 2022 ...

2022-04-26 12:30:00

Rigel Pharmaceuticals, Inc. announced that they will report Q1, 2022 results After-Market on May 03, 2022

Neutral

Rigel Pharmaceuticals, Inc., Q1 2022 Earnings C...

2022-04-26 12:30:00

Rigel Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 03, 2022

Neutral

Rigel Pharmaceuticals, Inc. - Shareholder/Analyst Call

2022-04-05 20:36:00

Annual General Meeting

Neutral

Rigel Pharmaceuticals, Inc., Annual General Mee...

2022-04-05 20:36:00

Rigel Pharmaceuticals, Inc., Annual General Meeting, May 19, 2022, at 07:30 Pacific Daylight. Agenda: To consider electing the two nominees na...

Negative

Rigel Pharmaceuticals, Inc. Appoints Kamil Ali-...

2021-12-16 14:00:00

Rigel Pharmaceuticals, Inc. announced that it has appointed Kamil Ali-Jackson to the company's Board of Directors. Ms. Ali-Jackson brings near...

Neutral

Rigel Pharmaceuticals, Inc. Presents at Piper S...

2021-11-22 15:06:00

Rigel Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, Unit...

Neutral

Rigel Pharmaceuticals, Inc. Presents at 12th An...

2021-11-09 12:30:00

Rigel Pharmaceuticals, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdo...

Neutral

Rigel Pharmaceuticals, Inc. Presents at Piper S...

2021-11-09 12:30:00

Rigel Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM. Speakers...

Neutral

Rigel Pharmaceuticals, Inc., Q3 2021 Earnings C...

2021-10-26 11:30:00

Rigel Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 02, 2021

Neutral

Rigel Pharmaceuticals, Inc. to Report Q3, 2021 ...

2021-10-26 11:30:00

Rigel Pharmaceuticals, Inc. announced that they will report Q3, 2021 results After-Market on Nov 02, 2021

Neutral

Piper Sandler Companies, Piper Sandler 33rd Ann...

2021-10-25 10:00:00

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.

Neutral

Rigel Pharmaceuticals, Inc. Presents at H.C. Wa...

2021-09-02 12:03:00

Rigel Pharmaceuticals, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York ...

Neutral

Rigel Pharmaceuticals, Inc. Presents at Cantor ...

2021-09-02 12:03:00

Rigel Pharmaceuticals, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-28-2021 04:40 PM. Venue: New York, United States. Speake...

Neutral

Rigel Pharmaceuticals, Inc. Presents at Citi’s ...

2021-09-01 18:36:00

Rigel Pharmaceuticals, Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-10-2021 12:30 PM. Venue: New York, United States....

Positive

Rigel Pharmaceuticals, Inc. Announces Data from...

2021-09-01 11:30:00

Rigel Pharmaceuticals, Inc. announced the publication of results from a Phase 2 clinical trial evaluating the safety of fostamatinib for the t...

Positive

Rigel Pharmaceuticals, Inc. Provides Update on ...

2021-08-13 20:16:00

Rigel Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has informed the Company that clinical data submitted in late...

Neutral

Rigel Pharmaceuticals, Inc. Provides Operating ...

2021-08-03 20:30:00

Rigel Pharmaceuticals, Inc. provided operating guidance for the third quarter of 2021. The company expects to see continued growth in the thir...

Neutral

Rigel Pharmaceuticals, Inc. has filed a Shelf R...

2021-08-03 00:00:00

Rigel Pharmaceuticals, Inc. has filed a Shelf Registration. Security Name: Common Stock Security Name: Preferred Stock Security Name:...

Neutral

Rigel Pharmaceuticals, Inc. to Report Q2, 2021 ...

2021-07-27 11:30:00

Rigel Pharmaceuticals, Inc. announced that they will report Q2, 2021 results After-Market on Aug 03, 2021

Neutral

Rigel Pharmaceuticals, Inc., Q2 2021 Earnings C...

2021-07-27 11:30:00

Rigel Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 03, 2021

Neutral

Rigel Pharmaceuticals, Inc. Presents at ISTH 20...

2021-07-14 13:00:00

Rigel Pharmaceuticals, Inc. Presents at ISTH 2021 Virtual Congress, Jul-18-2021 12:30 PM.

Neutral

Rigel Pharmaceuticals, Inc. Presents at 29th Co...

2021-07-14 12:57:00

Rigel Pharmaceuticals, Inc. Presents at 29th Congress of the International Society on Thrombosis and Haemostasis 2021, Jul-17-2021 .

Positive

Rigel Pharmaceuticals, Inc. to Highlight Data f...

2021-07-14 11:30:00

Rigel Pharmaceuticals, Inc. announced that data from its clinical development program for TAVALISSE® (fostamatinib disodium hexahydrate) table...

Neutral

International Society on Thrombosis and Haemost...

2021-07-07 07:14:00

International Society on Thrombosis and Haemostasis, 29th Congress of the International Society on Thrombosis and Haemostasis 2021, Jul 17, 20...

Neutral

Rigel Pharmaceuticals, Inc.'s Fostamatinib Sele...

2021-06-29 11:30:00

Rigel Pharmaceuticals, Inc. announced that fostamatinib, the Company's novel oral spleen tyrosine kinase (SYK) inhibitor, has been selected fo...

Positive

Rigel Pharmaceuticals, Inc. Announces Top-Line Results from Forward Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia

2022-06-08 11:00:00

Rigel Pharmaceuticals, Inc. announced top-line efficacy and safety data from the FORWARD Phase 3 clinical trial, a global, multi-center, randomized, double-blind, placebo-controlled trial of fostamatinib in patients with warm autoimmune hemolytic anemia (wAIHA). The trial did not demonstrate statistical significance in the primary efficacy endpoint of durable hemoglobin response in the overall study population. In a post-hoc regional analysis of U.S., Canadian, Australian, and Western European trial sites, patients treated with fostamatinib had a favorable durable hemoglobin response compared to placebo, whereas in the Eastern European trial sites patients did not. Rigel plans to continue analyzing the data to understand the geographical differences in patient disease characteristics and outcomes and discuss these findings with the U.S. Food and Drug Administration (FDA). The safety and tolerability profile in the FORWARD trial was consistent with the existing fostamatinib safetydatabase. Efficacy Results: The trial includes 90 patients in three pre-specified geographic regions, 14 sites in the U.S., Canada, and Australia; 16 sites in Western Europe (Austria, Germany, Spain, France, Italy, Belgium, U.K., Netherlands, Norway); and 16 sites in Eastern Europe (Bulgaria, Czech Republic, Russia, Ukraine, Georgia, Belarus, Serbia). Patients were randomized 1:1 to receive fostamatinib or matching placebo twice daily for 24 weeks. The primary efficacy endpoint of durable hemoglobin (Hgb) response was defined as achieving a Hgb =10 g/dL with an increase from baseline =2 g/dL on three consecutive available visits during the 24-week treatment period. The trial also included key secondary endpoints, including hemoglobin response on at least one visit, change in Hgb from baseline of =2 g/dL, use of permitted rescue therapy after week 4, change in Hgb from baseline to end of treatment and change from baseline to week 24 in Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F) scale.

Neutral

Rigel Pharmaceuticals, Inc. - Special Call

2022-06-08 11:00:00

Rigel Pharmaceuticals, Inc. - Special Call

Neutral

Knight Therapeutics Inc. Enters into Exclusive License and Supply Agreements with Rigel Pharmaceuticals to Commercialize Fostamatinib in Latin America

2022-05-24 11:30:00

Knight Therapeutics Inc. announced that it has entered into exclusive license and supply agreements with Rigel Pharmaceuticals granting Knight the rights to commercialize fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in Latin America. Fostamatinib is commercially available in the United States under the brand name TAVALISSE® (fostamatinib disodium hexahydrate) and in Europe under the brand name TAVLESSE® for the treatment of chronic immune thrombocytopenia (ITP). Fostamatinib is also currently being studied in a Phase 3 clinical trial for the treatment of warm autoimmune hemolytic anemia (wAIHA)1 and in two Phase 3 clinical trials for the treatment of hospitalized patients with COVID-19. Under the terms of the agreement, Rigel will receive an upfront cash payment, with the potential for additional regulatory and commercial milestones, and stepped-up royalties based on tiered net sales. In return, Knight receives exclusive rights to fostamatinib in all potential indications, including chronic ITP, wAIHA, and COVID-19 in Latin America.

Neutral

Rigel Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 03, 2022

2022-04-26 12:30:00

Rigel Pharmaceuticals, Inc. announced that they will report Q1, 2022 results After-Market on May 03, 2022

Neutral

Rigel Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 03, 2022

2022-04-26 12:30:00

Rigel Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 03, 2022

Neutral

Rigel Pharmaceuticals, Inc. - Shareholder/Analyst Call

2022-04-05 20:36:00

Annual General Meeting

Neutral

Rigel Pharmaceuticals, Inc., Annual General Meeting, May 19, 2022

2022-04-05 20:36:00

Rigel Pharmaceuticals, Inc., Annual General Meeting, May 19, 2022, at 07:30 Pacific Daylight. Agenda: To consider electing the two nominees named in this proxy statement, kamil ali-jackson and jane wasman, to the board of directors of the company, to hold office until the company’s 2025 annual meeting of stockholders; to consider approval of an amendment to 2018 equity incentive plan, as amended (the “amended 2018 plan”), to add an additional 5,000,000 shares to the number of shares of common stock authorized for issuance under the amended 2018 plan; to consider approval on an advisory basis, the compensation of the company’s named executive officers, as disclosed in the accompanying proxy statement; to ratify the selection of Ernst & young LLP as the independent registered public accounting firm of the company for its fiscal year ending December 31, 2022; and to consider similar matters.

Negative

Rigel Pharmaceuticals, Inc. Appoints Kamil Ali-Jackson to Board of Directors

2021-12-16 14:00:00

Rigel Pharmaceuticals, Inc. announced that it has appointed Kamil Ali-Jackson to the company's Board of Directors. Ms. Ali-Jackson brings nearly four decades of biopharmaceutical industry experience to Rigel, including expertise in negotiating licensing, joint-venture, and M&A transactions to drive strategic growth. Ms. Ali-Jackson currently serves as the chief legal officer, chief compliance officer, and corporate secretary for publicly traded Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company that she co-founded in 2012 and led the team which took the company public in 2015. She will be retiring from her role at Aclaris on January 3, 2022. Ms. Ali-Jackson has extensive transaction experience with companies such as Merck & Co., Inc., Endo Pharmaceuticals, Inc., and Dr. Reddy's Laboratories, Inc., including negotiating acquisitions of intellectual property assets and licensing agreements for drug products in various stages of development across multiple therapeutic areas. She was the lead negotiator for the acquisition of intellectual property rights for Merck's billion-dollar human papillomavirus vaccine and legal counsel for its gastroenterology product franchise, which led to the creation of a multi-billion joint venture between Merck and Astra AB that then became part of AstraZeneca. Previously, Ms. Ali-Jackson co-founded and served as chief legal officer, chief compliance officer, and general counsel for several other private biopharmaceutical or specialty pharmaceutical companies, including Ceptaris Therapeutics, Inc. and Ception Therapeutics, Inc., both of which were successfully acquired in multimillion-dollar acquisitions. She is currently a member of the board of directors, audit and compensation committees, and is the chair of the nominating and corporate governance committee of PDS Biotechnology Corporation, a publicly-traded clinical-stage immunotherapy company, as well as on the board of other private companies.

Neutral

Rigel Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021

2021-11-22 15:06:00

Rigel Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.

Neutral

Rigel Pharmaceuticals, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM

2021-11-09 12:30:00

Rigel Pharmaceuticals, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom. Speakers: Dean L. Schorno, Executive VP & CFO.

Neutral

Rigel Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM

2021-11-09 12:30:00

Rigel Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM. Speakers: Dean L. Schorno, Executive VP & CFO.

Neutral

Rigel Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 02, 2021

2021-10-26 11:30:00

Rigel Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 02, 2021

Neutral

Rigel Pharmaceuticals, Inc. to Report Q3, 2021 Results on Nov 02, 2021

2021-10-26 11:30:00

Rigel Pharmaceuticals, Inc. announced that they will report Q3, 2021 results After-Market on Nov 02, 2021

Neutral

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021

2021-10-25 10:00:00

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.

Neutral

Rigel Pharmaceuticals, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM

2021-09-02 12:03:00

Rigel Pharmaceuticals, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, New York City, New York, United States. Speakers: Dean L. Schorno, Executive VP & CFO.

Neutral

Rigel Pharmaceuticals, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-28-2021 04:40 PM

2021-09-02 12:03:00

Rigel Pharmaceuticals, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-28-2021 04:40 PM. Venue: New York, United States. Speakers: Raul R. Rodriguez, President, CEO & Director.

Neutral

Rigel Pharmaceuticals, Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-10-2021 12:30 PM

2021-09-01 18:36:00

Rigel Pharmaceuticals, Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-10-2021 12:30 PM. Venue: New York, United States. Speakers: Raul R. Rodriguez, President, CEO & Director.

Positive

Rigel Pharmaceuticals, Inc. Announces Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases

2021-09-01 11:30:00

Rigel Pharmaceuticals, Inc. announced the publication of results from a Phase 2 clinical trial evaluating the safety of fostamatinib for the treatment of hospitalized patients with COVID-19, in Clinical Infectious Diseases, an official publication of the Infectious Disease Society of America. The study was sponsored by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), in collaboration with Inova Health System. The results from the 59 patient Phase 2 trial demonstrated that the addition of fostamatinib to standard of care (SOC), which included the antiviral remdesivir and the steroid dexamethasone, was well tolerated and associated with clinically meaningful improvement in clinical outcomes in hospitalized COVID-19 patients who required supplemental oxygen. While the study was not powered to test clinical efficacy, numerous prespecified secondary endpoints consistently favored fostamatinib, including mortality, time to sustained recovery, change in ordinal scale assessment, number of days on oxygen, and number of days in the ICU, suggesting that fostamatinib may provide an additional therapeutic benefit compared to current SOC alone.

Positive

Rigel Pharmaceuticals, Inc. Provides Update on COVID-19 Program

2021-08-13 20:16:00

Rigel Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has informed the Company that clinical data submitted in late-May from a 59-patient NIH/NHLBI-sponsored Phase 2 trial of fostamatinib to treat hospitalized patients suffering from COVID-19 are insufficient for an emergency use authorization (EUA) at this time. The FDA noted in their response that they remain committed to working with Rigel in the development of fostamatinib for COVID-19 as the Company is currently conducting a larger Phase 3 clinical trial evaluating fostamatinib in hospitalized patients with COVID-19. Fostamatinib Clinical Development Program in COVID-19: The broader clinical development program for fostamatinib is comprised of three ongoing studies and a recently completed Phase 2 study. These studies are evaluating a wide range of hospitalized patients, including those not on oxygen therapy, who are experiencing mild to severe COVID-19-related complications: Rigel-led Phase 3 Trial: This ongoing Phase 3 clinical trial will evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients without respiratory failure that have certain high-risk prognostic factors. This multi-center, double-blind, placebo-controlled study will enroll ~308 evaluable patients to either fostamatinib plus SOC or matched placebo plus SOC (1:1). The primary endpoint of this study is the proportion of patients who progress to severe/critical disease within 29 days. The study has enrolled ~176 patients as of August 12, 2021, and enrollment is expected to be complete by year-end. ACTIV-4 Host Tissue Phase 3 Trial: The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) study, initiated and funded by the National Heart Lung and Blood Institute (NHLBI), part of the National Institutes of Health, is a multi-site, randomized, placebo-controlled trial of therapies, including fostamatinib, targeting the host response to COVID-19 in hospitalized patients. The Master Protocol is designed to be flexible in the number of study arms, the use of a single placebo group, and the stopping and adding of new therapies. Each active arm will include approximately 300 patients. Eligible participants will include patients hospitalized for COVID-19 with laboratory-confirmed SARS-CoV-2 infection on oxygen therapy. The primary outcome is oxygen-free days through day 28. Secondary outcomes include hospital mortality, use of mechanical ventilation, and WHO scale scores. The study enrolled its first patient on July 22, 2021. Imperial College of London IST: The Imperial College London Investigator-Sponsored Trial (IST) is a two-stage, open-label, controlled clinical trial of patients randomized (1:1:1) to fostamatinib, ruxolitinib, or SOC. The primary objective will be to determine the efficacy of fostamatinib and the efficacy of ruxolitinib compared to SOC to reduce the proportion of hospitalized patients progressing from mild or moderate to severe COVID-19 pneumonia. Rigel is providing support for this trial along with Novartis. NIH/NHLBI-sponsored Phase 2 Trial: This randomized, double-blind, placebo-controlled study, which has been completed, evaluated the safety of fostamatinib plus SOC and matched placebo plus SOC (1:1) in hospitalized patients with COVID-19 requiring supplemental oxygen. The primary endpoint was the cumulative incidence of serious adverse events (SAEs) by Day 29. As previously announced, the study met its primary endpoint of safety and provided evidence of broad and consistent improvement in numerous secondary endpoints including mortality, time to sustained recovery, change in ordinal scale assessment, number of days on oxygen, and number of days in the ICU. Results from this study have been submitted for publication in a peer-reviewed medical journal.

Neutral

Rigel Pharmaceuticals, Inc. Provides Operating Guidance for the Third Quarter of 2021

2021-08-03 20:30:00

Rigel Pharmaceuticals, Inc. provided operating guidance for the third quarter of 2021. The company expects to see continued growth in the third quarter in bottles shipped to patients and clinics, similar to what was in the second quarter.

Neutral

Rigel Pharmaceuticals, Inc. has filed a Shelf Registration.

2021-08-03 00:00:00

Rigel Pharmaceuticals, Inc. has filed a Shelf Registration. Security Name: Common Stock Security Name: Preferred Stock Security Name: Debt Securities Security Name: Warrants Transaction Features: Omnibus/Universal Shelf Registration

Neutral

Rigel Pharmaceuticals, Inc. to Report Q2, 2021 Results on Aug 03, 2021

2021-07-27 11:30:00

Rigel Pharmaceuticals, Inc. announced that they will report Q2, 2021 results After-Market on Aug 03, 2021

Neutral

Rigel Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 03, 2021

2021-07-27 11:30:00

Rigel Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 03, 2021

Neutral

Rigel Pharmaceuticals, Inc. Presents at ISTH 2021 Virtual Congress, Jul-18-2021 12:30 PM

2021-07-14 13:00:00

Rigel Pharmaceuticals, Inc. Presents at ISTH 2021 Virtual Congress, Jul-18-2021 12:30 PM.

Neutral

Rigel Pharmaceuticals, Inc. Presents at 29th Congress of the International Society on Thrombosis and Haemostasis 2021, Jul-17-2021

2021-07-14 12:57:00

Rigel Pharmaceuticals, Inc. Presents at 29th Congress of the International Society on Thrombosis and Haemostasis 2021, Jul-17-2021 .

Positive

Rigel Pharmaceuticals, Inc. to Highlight Data from the Clinical Development Program for TAVALISSE® (Fostamatinib Disodium Hexahydrate) Tablets at the Upcoming International Society on Thrombosis and Haemostasis Virtual Congress

2021-07-14 11:30:00

Rigel Pharmaceuticals, Inc. announced that data from its clinical development program for TAVALISSE® (fostamatinib disodium hexahydrate) tablets will be highlighted in two presentations at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress, taking place online from July 17 – 21, 2021. Fostamatinib is an oral drug designed to inhibit spleen tyrosine kinase (SYK), a key signaling component of the autoimmune process that leads to platelet destruction in immune thrombocytopenia (ITP). Fostamatinib is commercially available in the U.S. under the brand name TAVALISSE (fostamatinib disodium hexahydrate) tablets and is the first and only SYK inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to a previous treatment. All ePosters will be made available online during the Poster Networking Session on the conference website on July 17, 2021, at 4:00 p.m. Eastern Time. Abstract Presentation Number: PB0815: Title: Time Course of Response to Fostamatinib, an Oral Spleen Tyrosine Kinase (SYK) Inhibitor for the Treatment of Immune Thrombocytopenia (ITP); Presenting Author: Michelle Sholzberg, MDCM, Division Head of Hematology-Oncology and the Medical Director of the Coagulation Laboratory at St. Michael's Hospital, Toronto. In a post-hoc analysis of the Rigel FIT Phase 3 program, for the 58 patients treated for =1 year, clinical endpoints were assessed in 3-month increments over the first year: Patients treated for =1 year, had a response rate (achieved a platelet count =50,000/µL) of 91% (53/58), 71% (41/58) within 12 weeks, with median platelet counts continuing to increase in each 3-month period of the first year of treatment. Incidence of bleeding events and use of rescue therapy continually decreased in these 58 patients over the first year of treatment with fostamatinib. Abstract Presentation Number: PB0833: Title: Treatment of Immune Thrombocytopenia (ITP) in the COVID-19 Era: Fostamatinib, an Oral Spleen Tyrosine Kinase (SYK) Inhibitor; Presenting Authors: Nichola Cooper, Asad Charania, Alice Hart, Christine Ademokun, and Robert Numerof. A review of safety and efficacy data from the fostamatinib Phase 3 program evaluated dosing and titration, incidence of infections, thrombocytosis and thrombosis, and the immune response to pathogens to assess the potential benefits of TAVALISSE for the unique challenges of treating ITP during the pandemic. Findings include: A reduced need for office visits due to oral administration, easy titration, and low incidence of thrombocytosis. Fostamatinib's unique mechanism of action provide increased hemostasis and may reduce the risk of thrombosis. Fostamatinib is not an immunosuppressant drug.

Neutral

International Society on Thrombosis and Haemostasis, 29th Congress of the International Society on Thrombosis and Haemostasis 2021, Jul 17, 2021 through Jul 21, 2021

2021-07-07 07:14:00

International Society on Thrombosis and Haemostasis, 29th Congress of the International Society on Thrombosis and Haemostasis 2021, Jul 17, 2021 through Jul 21, 2021.

Neutral

Rigel Pharmaceuticals, Inc.'s Fostamatinib Selected for National Institutes of Health (NIH) ACTIV-4 COVID-19 Clinical Trial

2021-06-29 11:30:00

Rigel Pharmaceuticals, Inc. announced that fostamatinib, the Company's novel oral spleen tyrosine kinase (SYK) inhibitor, has been selected for a National Institutes of Health (NIH) ACTIV-4 (Accelerating COVID-19 Therapeutic Interventions and Vaccines) trial in hospitalized patients with COVID-19. The ACTIV-4 Host Tissue trial is a large, multi-site trial funded by the National Heart, Lung, and Blood Institute (NHLBI) of the NIH and coordinated by Vanderbilt University Medical Center (VUMC). The trial is evaluating treatments, including fostamatinib, that aim to protect and heal host tissues in hospitalized patients with COVID-19. This study follows a recently completed NHLBI/NIH-sponsored Phase 2 study (NCT04579393), with positive topline results, that evaluated fostamatinib in hospitalized adults with COVID-19. The study met its primary endpoint of safety and showed broad and consistent improvement in numerous efficacy endpoints including mortality, ordinal scale assessment, and number of days in the ICU. These data were submitted as part of a request for an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for fostamatinib in hospitalized patients diagnosed with COVID-19. These data have also been submitted for publication in a peer-reviewed medical journal. The Collaborative Network of Networks for Evaluating COVID-19 Therapeutic Strategies (CONNECTS) Master Protocol for Clinical Trials Targeting Macro-, Micro-immuno-thrombosis, Vascular Hyperinflammation, and Hypercoagulability and Renin-angiotensin-aldosterone System (RAAS) in Hospitalized Patients With COVID-19 (ACTIV-4 Host Tissue) is a multi-site, randomized, placebo-controlled trial of therapies, including fostamatinib, targeting the host response to COVID-19 in hospitalized patients. The Master Protocol is designed to be flexible in the number of study arms, the use of a single placebo group, and the stopping and adding of new therapies. Each active arm will include approximately 300 patients. Eligible participants will include patients hospitalized for COVID-19 with laboratory confirmed SARS-CoV-2 infection on oxygen therapy. The primary outcome is oxygen free days through day 28. Secondary outcomes include hospital mortality, use of mechanical ventilation, and WHO scale scores. The study is part of Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), initiated and funded by the NHLBI, part of the NIH. ACTIV is a public-private partnership that unites partners from government, industry, academic and non-profit organizations to prioritize and speed development of the most promising COVID-19 treatments. COVID-19 is the infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). SARS-CoV-2 primarily infects the upper and lower respiratory tract and can lead to acute respiratory distress syndrome (ARDS). Additionally, some patients develop other organ dysfunction including myocardial injury, acute kidney injury, shock resulting in endothelial dysfunction and subsequently micro and macrovascular thrombosis. Much of the underlying pathology of SARS-CoV-2 is thought to be secondary to a hyperinflammatory immune response associated with increased risk of thrombosis. SYK is involved in the intracellular signaling pathways of many different immune cells. Therefore, SYK inhibition may improve outcomes in patients with COVID-19 via inhibition of key Fc gamma receptor (Fc?R) and c-type lectin receptor (CLR) mediated drivers of pathology such as pro-inflammatory cytokine release by monocytes and macrophages, production of neutrophil extracellular traps (NETs) by neutrophils, and platelet aggregation.3,4,5,6 Furthermore, SYK inhibition in neutrophils and platelets may lead to decreased thrombo-inflammation, alleviating organ dysfunction in critically ill patients with COVID-19.

Fundamental Summary

Rigel Pharmaceuticals published concerning results on 2022-05-03. Their growth, value, and income factors indicate a poor execution and strategy, which isn't generating exciting growth. These results suggest a challenging future for Rigel Pharmaceuticals's stock. As such, Rigel Pharmaceuticals received an overall score of 52 and a UNDERPERFORM recommendation.

Rigel Pharmaceuticals reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 16.74 million compared to USD 81.02 million a year ago. Net loss was USD 27.45 million compared to net income of USD 39.5 million a year ago. Basic loss per share from continuing operations was USD 0.16 compared to basic earnings per share from continuing operations of USD 0.23 a year ago. Diluted loss per share from continuing operations was USD 0.16 compared to diluted earnings per share from continuing operations of USD 0.22 a year ago.

Business Description

Rigel Pharmaceuticals, a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals was incorporated in 1996 and is headquartered in South San Francisco, California.

Sector Overview

Rigel Pharmaceuticals is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Rigel Pharmaceuticals's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 149.1 -10.9% 67
Liabilities 142.3 3.9% 53
Price to Book 56.2 275.3% 63
Cash & Equivalents 24.7 30.6% 90
Equity 6.8 -77.6% 51
EBITDA -82.4 -372.6% 44
Total Revenues 77.5 -44.2% 99
Parameter Value Change Score
Return on Equity -199.4 -258.5% 82
Net Cashflow 4.6 140.3% 42
Capital Expenditure -0.8 -24.4% 46
Asset Turnover 0.4 -57.5% 40
Free Cashflow -0.0 -111.1% 40

* All values are TTM

The below chart reflects Rigel Pharmaceuticals's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Rigel Pharmaceuticals's peer average final assessment score stands on 63.0, Rigel Pharmaceuticals's score is 52.

  •  RIGL
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amgen Inc. 130.1B 69 78 81
Hold
77
77 0 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 1 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 3 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 4 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 5 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 7 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 8 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 9 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 10 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 11 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 12 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 13 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 15 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 16 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 17 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 18 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 19 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 20 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 22 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 23 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 24 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 26 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 28 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 29 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 30 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 31 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 32 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 33 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 34 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 36 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 37 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 38 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 39 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 40 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 41 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 42 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 43 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 44 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 45 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 46 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 47 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 48 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 49 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 50 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 51 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 52 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 53 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 54 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 55 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 56 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 57 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 58 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 59 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 60 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 61 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 62 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 63 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 64 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 65 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 66 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 67 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 68 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 69 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 70 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 73 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 74 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 75 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 77 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 78 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 79 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 80 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 81 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 82 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 83 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 84 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 85 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 86 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 92 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 93 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Rigel Pharmaceuticals's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Rigel Pharmaceuticals's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 42.

Bearish 42
Close Price 1.09
52W Low 0.67
52W High 4.5
5D MA 1.13
50D MA 1.83
200D MA 2.68
MACD -0.22
RSI 7.73
STOCH 76.24

Balance Sheet Analysis

Overall, Rigel Pharmaceuticals's critical balance sheet metrics appear to signal strong support and a high likelihood of positive growth going forward. Rigel Pharmaceuticals reported a positive trendline in their cash and cash equivalents metrics. Specifically, they reported that cash and cash equivalents were 24.7, representing 30.6% change from the last report. Its impressive cash and cash equivalents metrics should support upward pressure on its's stock price. Therefore, its cash and cash equivalents movement earned a score of 90. Also, The company's assets section could set high expectations for Rigel Pharmaceuticals's future attractiveness, as they went to 149.1, which is a -10.9% change from the last period. This growth should support upward pressure on its's stock price, which better captures their intrinsic value. Consequently, their asset movement received a grade of 67. At the same time, one critical balance sheet metric, Equity, was notably weak. Rigel Pharmaceuticals management produced disappointing equity metrics this period, which stood at 6.8, representing a -77.6% change. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. This performance is significantly less impressive than its peers and competitors. Its equity movement component, therefore, received a grade of 51. Consequently, the company's balance sheet earned a rank of 62.

Parameter Value Change Score
Assets 149.1 -10.9% 67
Liabilities 142.3 3.9% 53
Price to Book 56.2 275.3% 63
Cash & Equivalents 24.7 30.6% 90
Equity 6.8 -77.6% 51
* All values are TTM

The below chart describes Rigel Pharmaceuticals's performance as reflected on its balance sheet with respect to its peers. While Rigel Pharmaceuticals received a balance sheet score of 62, the average of its peers stands on 64.0.

  •  RIGL
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amgen Inc. 130.1B 72 68 86 53 62 69 0 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 1 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 3 1
BioNTech SE 34.0B 75 69 64 97 73 75 4 1
Seagen Inc. 32.9B 59 68 55 43 66 61 5 1
Biogen Inc. 29.7B 57 72 92 50 76 76 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 7 1
Incyte Corporation 16.8B 71 72 95 82 79 83 8 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 9 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 10 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 11 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 12 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 13 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 14 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 15 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 16 1
Alkermes plc 5.0B 63 66 46 54 71 62 17 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 18 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 19 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 20 1
Natera, Inc. 3.6B 73 65 43 95 42 54 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 22 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 23 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 24 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 26 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 28 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 29 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 30 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 31 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 32 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 33 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 34 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 36 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 37 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 38 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 39 1
Geron Corporation 566.2M 69 72 37 59 62 60 40 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 41 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 42 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 43 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 44 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 45 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 46 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 47 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 48 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 49 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 50 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 51 1
CureVac N.V. 2.6B 49 64 75 52 52 57 52 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 53 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 54 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 55 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 56 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 57 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 58 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 59 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 60 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 61 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 62 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 63 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 64 1
CareDx, Inc 1.2B 54 67 52 39 51 52 65 1
Vericel Corporation 1.1B 51 65 56 53 61 57 66 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 67 1
MannKind Corporation 957.2M 79 59 50 40 64 57 68 1
Merus N.V. 941.6M 59 68 50 83 81 70 69 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 70 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 72 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 73 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 74 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 75 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 76 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 77 1
Immatics N.V. 538.7M 56 70 84 95 73 76 78 1
Agenus Inc. 520.5M 73 62 37 55 60 54 79 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 80 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 81 1
Affimed N.V. 415.0M 56 66 63 56 47 54 82 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 83 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 84 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 85 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 86 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
AC Immune SA 299.8M 84 64 47 53 75 68 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 92 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 93 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Rigel Pharmaceuticals appears likely to maintain its strong income statement metrics and momentum going forward. Rigel Pharmaceuticals reported highly encouraging numbers for its revenue efficiency. This parameter often affects companies in the same industry and market capitalization by up to 13.1%. Their industry-leading revenue efficiency makes a strong case for upward pressure on its's stock price. The company's revenue efficiency, therefore, received a grade of 99. Also, Rigel Pharmaceuticals's reported return on equity (ROE) ratio was -199.4, representing a change of -258.5%. Its return factor metrics are even more remarkable when compared to their peers. Therefore, its return factors component earned a score of 82. On the other hand, EBITDA, jumped out as looking problematic. Rigel Pharmaceuticals's management didn't make significant improvements to their EBITDA this period. In terms of the raw numbers, EBITDA was reported as -82.4, which represents a -372.6% change from the last period. This parameter coud affect companies in the same industry and market capitalization by up to 24.4%. The company's EBITDA metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Therefore, their EBITDA component earned a score of 44. As the companie's management is doing an excellent job managing the critical metrics, the income statement was given a score of 64.

Parameter Value Change Score
EBITDA -82.4 -372.6% 44
Total Revenues 77.5 -44.2% 99
Return on Equity -199.4 -258.5% 82
* All values are TTM

The below chart describes Rigel Pharmaceuticals's performance as reflected on its income statement with respect to its peers. While Rigel Pharmaceuticals received a income statement score of 64 , the average of its peers stands on 66.0.

  •  RIGL
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amgen Inc. 130.1B 74 75 64 78 0 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 1 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 3 1
BioNTech SE 34.0B 41 89 75 79 4 1
Seagen Inc. 32.9B 54 65 70 62 5 1
Biogen Inc. 29.7B 90 57 73 70 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 7 1
Incyte Corporation 16.8B 59 77 60 73 8 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 9 1
United Therapeutics Corporation 10.6B 57 91 54 82 10 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 11 1
Exelixis, Inc. 6.7B 54 91 54 81 12 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 13 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 14 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 15 1
Ascendis Pharma A/S 5.2B 38 68 46 54 16 1
Alkermes plc 5.0B 69 55 81 62 17 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 18 1
Novavax, Inc. 4.0B 41 89 54 75 19 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 20 1
Natera, Inc. 3.6B 52 51 78 52 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 22 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 23 1
Insmed Incorporated 2.4B 51 58 73 57 24 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 26 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 28 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 29 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 30 1
IVERIC bio, Inc. 1.1B 84 58 79 70 31 1
FibroGen, Inc. 1.0B 48 74 63 67 32 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 33 1
ImmunoGen, Inc. 946.1M 40 73 71 64 34 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 36 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 37 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 38 1
AnaptysBio, Inc. 586.3M 97 50 77 68 39 1
Geron Corporation 566.2M 89 67 73 78 40 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 41 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 42 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 43 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 44 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 45 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 46 1
Precigen, Inc. 299.1M 57 87 59 79 47 1
bluebird bio, Inc. 288.7M 99 91 61 96 48 1
MacroGenics, Inc. 184.6M 95 56 74 71 49 1
Exact Sciences Corporation 7.2B 57 67 54 62 50 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 51 1
CureVac N.V. 2.6B 45 83 71 74 52 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 53 1
Abgenix Inc. 2.1B 47 47 47 47 54 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 55 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 56 1
Xencor, Inc. 1.6B 42 94 52 79 57 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 58 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 59 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 60 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 61 1
Veracyte, Inc. 1.4B 45 63 57 55 62 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 63 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 64 1
CareDx, Inc 1.2B 61 44 82 50 65 1
Vericel Corporation 1.1B 76 44 82 56 66 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 67 1
MannKind Corporation 957.2M 95 48 56 61 68 1
Merus N.V. 941.6M 48 60 59 54 69 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 70 1
Amarin Corporation plc 734.5M 95 44 82 63 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 72 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 73 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 74 1
CTI BioPharma Corp. 603.6M 84 50 62 59 75 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 76 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 77 1
Immatics N.V. 538.7M 37 93 53 77 78 1
Agenus Inc. 520.5M 57 83 45 74 79 1
Radius Health, Inc. 499.8M 94 71 68 82 80 1
Vaxart, Inc. 440.0M 99 51 72 68 81 1
Affimed N.V. 415.0M 95 49 75 66 82 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 83 1
MiMedx Group, Inc. 391.5M 87 43 83 59 84 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 85 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 86 1
Zymeworks Inc. 324.7M 58 53 77 56 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
AC Immune SA 299.8M 83 61 65 70 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 92 1
Chimerix, Inc. 178.4M 99 50 62 65 93 1
DermTech, Inc. 165.3M 49 48 78 52 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Rigel Pharmaceuticals's most recent cash flow report was not encouraging. Rigel Pharmaceuticals's asset turnover metrics were concerning and highlighted potential issues management is having effectively turning assets into sales efficiently. At filing, their asset turnover metrics were 0.4, representing a -57.5% change from the previous period. Companies in the same sector and market capitalization will usually be affected by up to 4.1 percent by this parameter. The company's asset turnover metrics seem especially problematic relative to their peers. Correspondingly, their asset turnover movement received a grade of 40. Also, Rigel Pharmaceuticals did a poor job related to generating and maintaining strong free cash flow this period, which stood at -0.0, representing a -111.1% change from the previous filing. Companies in the same industry and market capitalization are typically affected by this parameter by up to 2.6%. These free cash flow numbers show that management has not been executing well in generating critical cash flow while also encouraging growth. Consequently, their free cash flow movement received a grade of 40. However, we can we draw some encouragement from Rigel Pharmaceuticals's momentum in cash flow generation. Rigel Pharmaceuticals's management did a great job this period managing its capital expenditure (CapEx). In terms of the raw numbers, CapEx was reported as -0.8, which represents a -24.4% change from the last period. The company appears to be headed in the right direction regarding resource allocation, exhibiting prudent capital expenditure growth compared to its peers. The company's CapEx movement, therefore, received a grade of 46. Therefore, it received a cautionary score of 41.

Parameter Value Change Score
Net Cashflow 4.6 140.3% 42
Capital Expenditure -0.8 -24.4% 46
Asset Turnover 0.4 -57.5% 40
Free Cashflow -0.0 -111.1% 40
* All values are TTM

The below chart describes Rigel Pharmaceuticals's performance as reflected on its cash flow with respect to its peers. While Rigel Pharmaceuticals received a cash flow score of 41, the average of its peers stands on 68.0.

  •  RIGL
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amgen Inc. 130.1B 80 74 67 74 81 0 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 1 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 2 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 3 1
BioNTech SE 34.0B 73 97 50 52 72 4 1
Seagen Inc. 32.9B 53 53 50 87 58 5 1
Biogen Inc. 29.7B 58 54 90 73 66 6 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 7 1
Incyte Corporation 16.8B 78 79 92 74 84 8 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 9 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 10 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 11 1
Exelixis, Inc. 6.7B 79 90 89 83 87 12 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 13 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 14 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 15 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 16 1
Alkermes plc 5.0B 89 95 76 80 92 17 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 18 1
Novavax, Inc. 4.0B 62 38 63 54 60 19 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 20 1
Natera, Inc. 3.6B 52 54 56 84 58 21 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 22 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 23 1
Insmed Incorporated 2.4B 79 80 61 89 82 24 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 25 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 26 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 27 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 28 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 29 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 30 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 31 1
FibroGen, Inc. 1.0B 86 74 48 87 84 32 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 33 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 34 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 35 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 36 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 37 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 38 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 39 1
Geron Corporation 566.2M 78 68 49 81 77 40 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 41 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 42 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 43 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 44 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 45 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 46 1
Precigen, Inc. 299.1M 82 75 37 85 74 47 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 48 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 49 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 50 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 51 1
CureVac N.V. 2.6B 87 80 90 70 90 52 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 53 1
Abgenix Inc. 2.1B 66 53 45 59 58 54 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 55 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 56 1
Xencor, Inc. 1.6B 96 95 70 95 98 57 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 58 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 59 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 60 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 61 1
Veracyte, Inc. 1.4B 90 95 46 46 82 62 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 63 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 64 1
CareDx, Inc 1.2B 98 84 40 50 86 65 1
Vericel Corporation 1.1B 64 46 59 73 65 66 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 67 1
MannKind Corporation 957.2M 77 56 43 37 66 68 1
Merus N.V. 941.6M 70 71 74 53 71 69 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 70 1
Amarin Corporation plc 734.5M 52 40 74 55 55 71 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 72 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 73 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 74 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 75 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 76 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 77 1
Immatics N.V. 538.7M 82 95 56 99 86 78 1
Agenus Inc. 520.5M 57 43 52 77 58 79 1
Radius Health, Inc. 499.8M 64 40 37 56 57 80 1
Vaxart, Inc. 440.0M 72 56 53 38 65 81 1
Affimed N.V. 415.0M 72 57 95 43 74 82 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 83 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 84 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 85 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 86 1
Zymeworks Inc. 324.7M 52 65 45 83 57 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
AC Immune SA 299.8M 66 77 79 63 68 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 92 1
Chimerix, Inc. 178.4M 80 84 95 47 83 93 1
DermTech, Inc. 165.3M 60 51 45 86 58 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.